CRMD
SHORT CANDIDATEMeanRevComposite
28.50
Technical
1.50
Fundamental
37.50
Rank
—
Price
4.84
Hurst
0.22
As of
Nov 13, 2026
Daily
CorMedix Inc.
HealthcareBiotechnologyCorMedix is a biopharmaceutical firm developing treatments for serious medical conditions in the U.S. market. The company's primary product is DefenCath, a solution applied to catheters to prevent blood infections in kidney failure patients undergoing dialysis. Based in Parsippany, New Jersey, CorMedix was established in 2006 and operates in the medical therapeutic sector.
Market cap
$370.6M
P/E (trailing)
7.28
P/E (forward)
13.31
PEG ratio
3.46
Dividend yield
0.00%
Beta
1.48
52w range
4.65 – 13.02
Return on equity
+15.29%
Profit margin
+15.49%
Revenue growth
-47.70%
Earnings growth
—
Price history
1Y: 4.66 (-58.5%) · range 4.66–12.73
Cycle position
0/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 87 · STRONG SETUP · exit proximity 0
Conviction
52/ 100 · maturity 100%
VScore.4043
Buildup.2036
EMA entry setup.2587
Fundamentals.1538
Volume profile
POC
7.85
Price vs POC
-38.4%
Overhead supply
100%
Runway
+53.4%
Value area 7.21–8.66 · 100% of 120d volume overhead · heavy supply
An AI analyst read is ready for this ticker.Open the AI analyst
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.967 | Nov 13, 2026 |
| trader-sentiment | 0.720 | Nov 12, 2026 |
Peer cluster
NEUTRAL
Forward returns
Not yet labeled — the study prices these as positions mature.